1. Home
  2. IMNM vs KOP Comparison

IMNM vs KOP Comparison

Compare IMNM & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNM
  • KOP
  • Stock Information
  • Founded
  • IMNM 2006
  • KOP 1988
  • Country
  • IMNM United States
  • KOP United States
  • Employees
  • IMNM N/A
  • KOP N/A
  • Industry
  • IMNM Medicinal Chemicals and Botanical Products
  • KOP Forest Products
  • Sector
  • IMNM Health Care
  • KOP Basic Materials
  • Exchange
  • IMNM Nasdaq
  • KOP Nasdaq
  • Market Cap
  • IMNM 748.3M
  • KOP 646.3M
  • IPO Year
  • IMNM 2020
  • KOP 2006
  • Fundamental
  • Price
  • IMNM $8.84
  • KOP $33.69
  • Analyst Decision
  • IMNM Strong Buy
  • KOP Buy
  • Analyst Count
  • IMNM 5
  • KOP 1
  • Target Price
  • IMNM $26.40
  • KOP $64.00
  • AVG Volume (30 Days)
  • IMNM 1.0M
  • KOP 120.3K
  • Earning Date
  • IMNM 08-11-2025
  • KOP 08-07-2025
  • Dividend Yield
  • IMNM N/A
  • KOP 0.95%
  • EPS Growth
  • IMNM N/A
  • KOP N/A
  • EPS
  • IMNM N/A
  • KOP 1.22
  • Revenue
  • IMNM $10,938,000.00
  • KOP $2,051,000,000.00
  • Revenue This Year
  • IMNM N/A
  • KOP N/A
  • Revenue Next Year
  • IMNM $310.65
  • KOP $2.61
  • P/E Ratio
  • IMNM N/A
  • KOP $27.51
  • Revenue Growth
  • IMNM N/A
  • KOP N/A
  • 52 Week Low
  • IMNM $5.15
  • KOP $22.99
  • 52 Week High
  • IMNM $16.81
  • KOP $41.64
  • Technical
  • Relative Strength Index (RSI)
  • IMNM 50.27
  • KOP 63.31
  • Support Level
  • IMNM $8.35
  • KOP $31.55
  • Resistance Level
  • IMNM $9.34
  • KOP $34.20
  • Average True Range (ATR)
  • IMNM 0.53
  • KOP 0.90
  • MACD
  • IMNM -0.07
  • KOP 0.06
  • Stochastic Oscillator
  • IMNM 33.97
  • KOP 85.04

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

About KOP Koppers Holdings Inc.

Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.

Share on Social Networks: